Origins of DLBCL genes
Tier 1 DLBCL genes
126 total
Tier 2 DLBCL genes
179 total
Tier 3 DLBCL genes
386 total
References
1.
Desch AK, Hartung K, Botzen A, Brobeil A,
Rummel M, Kurch L, Georgi T, Jox T, Bielack S, Burdach S, Classen CF,
Claviez A, Debatin KM, Ebinger M, Eggert A, Faber J, Flotho C, Frühwald
M, Graf N, Jorch N, Kontny U, Kramm C, Kulozik A, Kühr J, Sykora KW,
Metzler M, Müller HL, Nathrath M, Nüßlein T, Paulussen M, Pekrun A,
Reinhardt D, Reinhard H, Rössig C, Sauerbrey A, Schlegel PG, Schneider
DT, Scheurlen W, Schweigerer L, Simon T, Suttorp M, Vorwerk P, Schmitz
R, Kluge R, Mauz-Körholz C, Körholz D, Gattenlöhner S, Bräuninger A. Genotyping circulating
tumor DNA of pediatric Hodgkin lymphoma.
Leukemia. 2020 Jan;34(1):151–166.
2.
Zhang J, Grubor V, Love CL, Banerjee A,
Richards KL, Mieczkowski PA, Dunphy C, Choi W, Au WY, Srivastava G,
Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers C,
Naresh K, Evens A, Gordon LI, Czader M, Gill JI, Hsi ED, Liu Q, Fan A,
Walsh K, Jima D, Smith LL, Johnson AJ, Byrd JC, Luftig MA, Ni T, Zhu J,
Chadburn A, Levy S, Dunson D, Dave SS. Genetic heterogeneity of diffuse
large B-cell lymphoma. Proceedings of the
National Academy of Sciences of the United States of America.
2013;110:1398–1403. PMCID: PMC3557051
3.
Barisic D, Chin CR, Meydan C, Teater M, Tsialta
I, Mlynarczyk C, Chadburn A, Wang X, Sarkozy M, Xia M, Carson SE,
Raggiri S, Debek S, Pelzer B, Durmaz C, Deng Q, Lakra P, Rivas M, Steidl
C, Scott DW, Weng AP, Mason CE, Green MR, Melnick A. ARID1A
orchestrates SWI/SNF-mediated
sequential binding of transcription factors with ARID1A
loss driving pre-memory B cell fate and
lymphomagenesis. Cancer Cell. 2024 Apr 8;42(4):583–604.e11.
4.
Love
C, Sun Z, Jima D, Li G, Zhang J, Miles R, Richards KL, Dunphy CH, Choi
WWL, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L,
Mann KP, Flowers CR, Naresh KN, Evens AM, Chadburn A, Gordon LI, Czader
MB, Gill JI, Hsi ED, Greenough A, Moffitt AB, McKinney M, Banerjee A,
Grubor V, Levy S, Dunson DB, Dave SS. The genetic landscape of mutations
in Burkitt lymphoma. Nat Genet. 2012 Dec;44(12):1321–1325.
PMCID: PMC3674561
5.
Reddy A, Zhang J, Davis NS, Moffitt AB, Love
CL, Waldrop A, Leppa S, Pasanen A, Meriranta L, Karjalainen-Lindsberg
ML, Nørgaard P, Pedersen M, Gang AO, Høgdall E, Heavican TB, Lone W,
Iqbal J, Qin Q, Li G, Kim SY, Healy J, Richards KL, Fedoriw Y,
Bernal-Mizrachi L, Koff JL, Staton AD, Flowers CR, Paltiel O,
Goldschmidt N, Calaminici M, Clear A, Gribben J, Nguyen E, Czader MB,
Ondrejka SL, Collie A, Hsi ED, Tse E, Au-Yeung RKH, Kwong YL, Srivastava
G, Choi WWL, Evens AM, Pilichowska M, Sengar M, Reddy N, Li S, Chadburn
A, Gordon LI, Jaffe ES, Levy S, Rempel R, Tzeng T, Happ LE, Dave T,
Rajagopalan D, Datta J, Dunson DB, Dave SS. Genetic and Functional
Drivers of Diffuse Large B Cell Lymphoma. Cell. 2017
Oct;171(2):481–494.e15. PMCID: PMC5659841
6.
Beà
S, Valdés-Mas R, Navarro A, Salaverria I, Martín-Garcia D, Jares P, Giné
E, Pinyol M, Royo C, Nadeu F, Conde L, Juan M, Clot G, Vizán P, Croce
LD, Puente DA, López-Guerra M, Moros A, Roue G, Aymerich M, Villamor N,
Colomo L, Martínez A, Valera A, Martín-Subero JI, Amador V, Hernández L,
Rozman M, Enjuanes A, Forcada P, Muntañola A, Hartmann EM, Calasanz MJ,
Rosenwald A, Ott G, Hernández-Rivas JM, Klapper W, Siebert R, Wiestner
A, Wilson WH, Colomer D, López-Guillermo A, López-Otín C, Puente XS,
Campo E. Landscape of
somatic mutations and clonal evolution in mantle cell lymphoma.
PNAS. 2013;110(45):18250–18255.
7.
Braggio E, Dogan A, Keats JJ, Chng WJ, Huang G,
Matthews JM, Maurer MJ, Law ME, Bosler DS, Barrett M, Lossos IS, Witzig
TE, Fonseca R. Genomic analysis of marginal zone and lymphoplasmacytic
lymphomas identified common and disease-specific abnormalities. Mod
Pathol. 2012 May;25(5):651–660. PMCID: PMC3341516
8.
Morin RD, Mendez-Lago M, Mungall AJ, Goya R,
Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field M,
Jackman S, Krzywinski M, Scott DW, Trinh DL, Tamura-Wells J, Li S, Firme
MR, Rogic S, Griffith M, Chan S, Yakovenko O, Meyer IM, Zhao EY, Smailus
D, Moksa M, Chittaranjan S, Rimsza L, Brooks-Wilson A, Spinelli JJ,
Ben-Neriah S, Meissner B, Woolcock B, Boyle M, McDonald H, Tam A, Zhao
Y, Delaney A, Zeng T, Tse K, Butterfield Y, Birol I, Holt R, Schein J,
Horsman DE, Moore R, Jones SJM, Connors JM, Hirst M, Gascoyne RD, Marra
MA. Frequent mutation of histone-modifying genes in
non-Hodgkin lymphoma. Nature. 2011 Jul
27;476(7360):298–303. PMCID: PMC3210554
9.
Pararajalingam P, Coyle KM, Arthur SE, Thomas
N, Alcaide M, Meissner B, Boyle M, Qureshi Q, Grande BM, Rushton C,
Slack GW, Mungall AJ, Tam CS, Agarwal R, Dawson SJ, Lenz G,
Balasubramanian S, Gascoyne RD, Steidl C, Connors J, Villa D, Audas TE,
Marra MA, Johnson NA, Scott DW, Morin RD. Coding and noncoding drivers
of mantle cell lymphoma identified through exome and genome sequencing.
Blood. 2020 Jul 30;136(5):572–584. PMCID: PMC7440974
10.
Xia
M, David L, Teater M, Gutierrez J, Wang X, Meydan C, Lytle A, Slack GW,
Scott DW, Morin RD, Onder O, Elenitoba-Johnson KSJ, Zamponi N,
Cerchietti L, Lu T, Philippar U, Fontan L, Wu H, Melnick AM. BCL10
Mutations Define Distinct Dependencies Guiding Precision Therapy
for DLBCL. Cancer Discov. 2022 Aug 5;12(8):1922–1941.
PMCID: PMC9357155
11.
Tanaka S, Louie DC, Kant JA, Reed JC. Frequent incidence of
somatic mutations in translocated BCL2 oncogenes of
non-Hodgkin’s lymphomas. Blood. 1992 Jan
1;79(1):229–237.
12.
Bal
E, Kumar R, Hadigol M, Holmes AB, Hilton LK, Loh JW, Dreval K, Wong JCH,
Vlasevska S, Corinaldesi C, Soni RK, Basso K, Morin RD, Khiabanian H,
Pasqualucci L, Dalla-Favera R. Super-enhancer hypermutation alters
oncogene expression in B cell lymphoma. Nature. 2022
Jul;607(7920):808–815. PMCID: PMC9583699
13.
Grande BM, Gerhard DS, Jiang A, Griner NB,
Abramson JS, Alexander TB, Allen H, Ayers LW, Bethony JM, Bhatia K,
Bowen J, Casper C, Choi JK, Culibrk L, Davidsen TM, Dyer MA,
Gastier-Foster JM, Gesuwan P, Greiner TC, Gross TG, Hanf B, Harris NL,
He Y, Irvin JD, Jaffe ES, Jones SJM, Kerchan P, Knoetze N, Leal FE,
Lichtenberg TM, Ma Y, Martin JP, Martin MR, Mbulaiteye SM, Mullighan CG,
Mungall AJ, Namirembe C, Novik K, Noy A, Ogwang MD, Omoding A, Orem J,
Reynolds SJ, Rushton CK, Sandlund JT, Schmitz R, Taylor C, Wilson WH,
Wright GW, Zhao EY, Marra MA, Morin RD, Staudt LM. Genome-wide discovery
of somatic coding and noncoding mutations in pediatric endemic and
sporadic Burkitt lymphoma. Blood. 2019;133(12):1313–1324.
PMCID: PMC6428665
14.
Guo
D, Hong L, Ji H, Jiang Y, Lu L, Wang X, Huang H. The
Mutation of BTG2 Gene Predicts a Poor
Outcome in Primary Testicular Diffuse Large B-Cell
Lymphoma. J Inflamm Res. 2022;15:1757–1769. PMCID: PMC8923029
15.
Lenz G, Davis RE, Ngo VN, Lam L, George TC,
Wright GW, Dave SS, Zhao H, Xu W, Rosenwald A, Ott G, Müller-Hermelink
HK, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J,
Smeland EB, Fisher RI, Chan WC, Staudt LM. Oncogenic
CARD11 mutations in human diffuse large B cell
lymphoma. Science. 2008 Mar;319(5870):1676–1679.
16.
Wu
C, de Miranda NF, Chen L, Wasik AM, Mansouri L, Jurczak W, Galazka K,
Dlugosz-Danecka M, Machaczka M, Zhang H, Peng R, Morin RD, Rosenquist R,
Sander B, Pan-Hammarström Q. Genetic heterogeneity in primary and
relapsed mantle cell lymphomas: Impact of recurrent
CARD11 mutations. Oncotarget. 2016 Jun
21;7(25):38180–38190. PMCID: PMC5122381
17.
Schmitz R, Young RM, Ceribelli M, Jhavar S,
Xiao W, Zhang M, Wright G, Shaffer AL, Hodson DJ, Buras E, Liu X, Powell
J, Yang Y, Xu W, Zhao H, Kohlhammer H, Rosenwald A, Kluin P,
Müller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E,
Jaffe ES, Delabie J, Smeland EB, Ogwang MD, Reynolds SJ, Fisher RI,
Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pittaluga S,
Wilson W, Waldmann TA, Rowe M, Mbulaiteye SM, Rickinson AB, Staudt LM.
Burkitt lymphoma pathogenesis and therapeutic targets from structural
and functional genomics. Nature. 2012 Oct 4;490(7418):116–120. PMCID: PMC3609867
18.
Jallades L, Baseggio L, Sujobert P, Huet S,
Chabane K, Callet-Bauchu E, Verney A, Hayette S, Desvignes JP, Salgado
D, Levy N, Béroud C, Felman P, Berger F, Magaud JP, Genestier L, Salles
G, Traverse-Glehen A. Exome sequencing identifies recurrent
BCOR alterations and the absence of KLF2,
TNFAIP3 and MYD88 mutations in splenic diffuse
red pulp small B-cell lymphoma.
Haematologica. 2017 Oct;102(10):1758–1766. PMCID: PMC5622860
19.
Davis RE, Ngo VN, Lenz G, Tolar P, Young RM,
Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL,
Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G,
Müller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM,
Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Braziel
RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM.
Chronic active B-cell-receptor signalling in
diffuse large B-cell lymphoma. Nature. 2010
Jan;463(7277):88–92. PMCID: PMC2845535
20.
Panea R, Love C, Shingleton JR, Reddy A, Bailey
J, Moormann A, Otieno J, Ong’echa J, Oduor C, Schroêder K, Masalu N,
Chao N, Agajanian M, Major M, Fedoriw Y, Richards K, Rymkiewicz G, Miles
R, Alobeid B, Bhagat G, Flowers C, Ondrejka S, Hsi E, Choi W, Au-Yeung
R, Hartmann W, Lenz G, Meyerson H, Lin YY, Zhuang Y, Luftig M, Waldrop
A, Dave T, Thakkar D, Sahay H, Li G, Palus B, Seshadri V, Kim S,
Gascoyne R, Levy S, Mukhopadhyay M, Dunson D, Dave S. The whole genome
landscape of Burkitt lymphoma subtypes. Blood. 2019;
21.
Morin RD, Mungall K, Pleasance E, Mungall AJ,
Goya R, Huff RD, Scott DW, Ding J, Roth A, Chiu R, Corbett RD, Chan FC,
Mendez-Lago M, Trinh DL, Bolger-Munro M, Taylor G, Hadj Khodabakhshi A,
Ben-Neriah S, Pon J, Meissner B, Woolcock B, Farnoud N, Rogic S, Lim EL,
Johnson NA, Shah S, Jones S, Steidl C, Holt R, Birol I, Moore R, Connors
JM, Gascoyne RD, Marra MA. Mutational and structural analysis of diffuse
large B-cell lymphoma using whole-genome
sequencing. Blood. 2013 Aug 15;122(7):1256–1265. PMCID: PMC3744992
22.
Guo
B, Huang Y, Duan Y, Liao C, Cen H. SGK1 mutation status can
further stratify patients with germinal center B-cell-like diffuse large B-cell lymphoma into different prognostic
subgroups. Cancer Med. 2022 Mar;11(5):1281–1291. PMCID: PMC8894717
23.
Parry M, Rose-Zerilli MJJ, Gibson J, Ennis S,
Walewska R, Forster J, Parker H, Davis Z, Gardiner A, Collins A, Oscier
DG, Strefford JC. Whole exome sequencing identifies novel recurrently
mutated genes in patients with splenic marginal zone lymphoma. PLoS One.
2013;8(12):e83244. PMCID: PMC3862727
24.
Khodabakhshi AH, Morin RD, Fejes AP, Mungall
AJ, Mungall KL, Bolger-Munro M, Johnson NA, Connors JM, Gascoyne RD,
Marra MA, Birol I, Jones SJM. Recurrent targets of aberrant somatic
hypermutation in lymphoma. Oncotarget. 2012;3(11):1308–1319. PMCID: PMC3717795
25.
Gong C, Krupka JA, Gao J, Grigoropoulos NF,
Giotopoulos G, Asby R, Screen M, Usheva Z, Cucco F, Barrans S, Painter
D, Zaini NBM, Haupl B, Bornelöv S, Ruiz De Los Mozos I, Meng W, Zhou P,
Blain AE, Forde S, Matthews J, Khim Tan MG, Burke GAA, Sze SK, Beer P,
Burton C, Campbell P, Rand V, Turner SD, Ule J, Roman E, Tooze R,
Oellerich T, Huntly BJ, Turner M, Du MQ, Samarajiwa SA, Hodson DJ. Sequential inverse
dysregulation of the RNA helicases DDX3X and
DDX3Y facilitates MYC-driven
lymphomagenesis. Molecular Cell. 2021;
26.
de
Miranda NFCC, Georgiou K, Chen L, Wu C, Gao Z, Zaravinos A, Lisboa S,
Enblad G, Teixeira MR, Zeng Y, Peng R, Pan-Hammarström Q. Exome
sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese
patients. Blood. 2014 Oct 16;124(16):2544–2553. PMCID: PMC4199956
27.
Gomez F, Fisk B, McMichael JF, Mosior M, Foltz
JA, Skidmore ZL, Duncavage EJ, Miller CA, Abel H, Li YS, Russler-Germain
DA, Krysiak K, Watkins MP, Ramirez CA, Schmidt A, Martins Rodrigues F,
Trani L, Khanna A, Wagner JA, Fulton RS, Fronick CC, O’Laughlin MD,
Schappe T, Cashen AF, Mehta-Shah N, Kahl BS, Walker J, Bartlett NL,
Griffith M, Fehniger TA, Griffith OL. Ultra-Deep Sequencing
Reveals the Mutational Landscape of Classical
Hodgkin Lymphoma. Cancer Res Commun. 2023 Nov 15;3(11):2312–2330.
PMCID: PMC10648575
28.
Bohle V, Döring C, Hansmann M-L, Küppers R. Role of early B-cell factor 1 (EBF1) in
Hodgkin lymphoma. Leukemia. 2013 Mar;27(3):671–679.
29.
Thomas N, Dreval K, Gerhard DS, Hilton LK,
Abramson JS, Ambinder RF, Barta S, Bartlett NL, Bethony J, Bhatia K,
Bowen J, Bryan AC, Cesarman E, Casper C, Chadburn A, Cruz M, Dittmer DP,
Dyer MA, Farinha P, Gastier-Foster JM, Gerrie AS, Grande BM, Greiner T,
Griner NB, Gross TG, Harris NL, Irvin JD, Jaffe ES, Henry D, Huppi R,
Leal FE, Lee MS, Martin JP, Martin MR, Mbulaiteye SM, Mitsuyasu R,
Morris V, Mullighan CG, Mungall AJ, Mungall K, Mutyaba I, Nokta M,
Namirembe C, Noy A, Ogwang MD, Omoding A, Orem J, Ott G, Petrello H,
Pittaluga S, Phelan JD, Ramos JC, Ratner L, Reynolds SJ, Rubinstein PG,
Sissolak G, Slack G, Soudi S, Swerdlow SH, Traverse-Glehen A, Wilson WH,
Wong J, Yarchoan R, ZenKlusen JC, Marra MA, Staudt LM, Scott DW, Morin
RD. Genetic subgroups inform on pathobiology in adult and pediatric
Burkitt lymphoma. Blood. 2023 Feb 23;141(8):904–916. PMCID:
PMC10023728
30.
Scholl V, Stefanoff CG, Hassan R, Spector N,
Renault IZ. Mutations within the 5’
region of FAS/CD95 gene in nodal diffuse large
B-cell lymphoma. Leuk Lymphoma. 2007
May;48(5):957–963.
31.
Seeberger H, Starostik P, Schwarz S, Knörr C,
Kalla J, Ott G, Müller-Hermelink HK, Greiner A. Loss of
Fas (CD95/APO-1) regulatory
function is an important step in early MALT-type lymphoma development. Lab Invest.
2001 Jul;81(7):977–986.
32.
Schneider C, Kon N, Amadori L, Shen Q, Schwartz
FH, Tischler B, Bossennec M, Dominguez-Sola D, Bhagat G, Gu W, Basso K,
Dalla-Favera R. FBXO11 inactivation leads to abnormal
germinal-center formation and lymphoproliferative disease. Blood. 2016
Aug 4;128(5):660–666. PMCID: PMC9709922
33.
Saffie R, Zhou N, Rolland D, Önder Ö, Basrur V,
Campbell S, Wellen KE, Elenitoba-Johnson KSJ, Capell BC, Busino L.
FBXW7 Triggers Degradation of KMT2D to
Favor Growth of Diffuse Large B-cell
Lymphoma Cells. Cancer Res. 2020 Jun 15;80(12):2498–2511. PMCID:
PMC7417195
34.
Trinh DL, Scott DW, Morin RD, Mendez-Lago M, An
J, Jones SJM, Mungall AJ, Zhao Y, Schein J, Steidl C, Connors JM,
Gascoyne RD, Marra MA. Analysis of FOXO1 mutations in
diffuse large B-cell lymphoma. Blood.
2013;121(18):3666–3674. PMCID: PMC3643765
35.
Pasqualucci L, Trifonov V, Fabbri G, Ma J,
Rossi D, Chiarenza A, Wells VA, Grunn A, Messina M, Elliot O, Chan J,
Bhagat G, Chadburn A, Gaidano G, Mullighan CG, Rabadan R, Dalla-Favera
R. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011 Jul
31;43(9):830–837. PMCID: PMC3297422
36.
Arthur SE, Jiang A, Grande BM, Alcaide M,
Cojocaru R, Rushton CK, Mottok A, Hilton LK, Lat PK, Zhao EY, Culibrk L,
Ennishi D, Jessa S, Chong L, Thomas N, Pararajalingam P, Meissner B,
Boyle M, Davidson J, Bushell KR, Lai D, Farinha P, Slack GW, Morin GB,
Shah S, Sen D, Jones SJM, Mungall AJ, Gascoyne RD, Audas TE, Unrau P,
Marra MA, Connors JM, Steidl C, Scott DW, Morin RD. Genome-wide
discovery of somatic regulatory variants in diffuse large B-cell lymphoma. Nat Commun. 2018 Oct 1;9(1):4001.
PMCID: PMC6167379
37.
Qiu
Z, Khalife J, Ethiraj P, Jaafar C, Lin AP, Holder KN, Ritter JP, Chiou
L, Huelgas-Morales G, Aslam S, Zhang Z, Liu Z, Arya S, Gupta YK, Dahia
PLM, Aguiar RCT. IRF8-mutant B cell lymphoma
evades immunity through a CD74-dependent
deregulation of antigen processing and presentation in
MHCII complexes. Sci Adv. 2024 Jul 12;10(28):eadk2091.
PMCID: PMC11244530
38.
Choi J, Phelan JD, Wright GW, Häupl B, Huang
DW, Shaffer AL, Young RM, Wang Z, Zhao H, Yu X, Oellerich T, Staudt LM.
Regulation of B cell receptor-dependent NF-κB signaling by the tumor suppressor
KLHL14. Proc Natl Acad Sci U S A. 2020 Mar
17;117(11):6092–6102. PMCID: PMC7084139
39.
Hodkinson BP, Schaffer M, Brody JD, Jurczak W,
Carpio C, Ben-Yehuda D, Avivi I, Forslund A, Özcan M, Alvarez J,
Ceulemans R, Fourneau N, Younes A, Balasubramanian S. Biomarkers of
response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or
Richter’s transformation. Transl Oncol. 2021
Jan;14(1):100977. PMCID: PMC7723809
40.
Meriranta L, Sorri S, Huse K, Liu X, Spasevska
I, Zafar S, Chowdhury I, Dufva O, Sahlberg E, Tandaric L,
Karjalainen-Lindsberg ML, Hyytiainen M, Varjosalo M, Myklebust JH, Leppa
S. Disruption of
KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-cell Lymphoma. Blood Cancer Discov. 2024 Apr
17;
41.
Ganapathi KA, Jobanputra V, Iwamoto F, Jain P,
Chen J, Cascione L, Nahum O, Levy B, Xie Y, Khattar P, Hoehn D, Bertoni
F, Murty VV, Pittaluga S, Jaffe ES, Alobeid B, Mansukhani MM, Bhagat G.
The genetic landscape
of dural marginal zone lymphomas. Oncotarget. Impact Journals; 2016
May 27;7(28):43052–43061.
42.
Zhang J, Jima D, Moffitt AB, Liu Q, Czader M,
Hsi ED, Fedoriw Y, Dunphy CH, Richards KL, Gill JI, Sun Z, Love C,
Scotland P, Lock E, Levy S, Hsu DS, Dunson D, Dave SS. The genomic
landscape of mantle cell lymphoma is related to the epigenetically
determined chromatin state of normal B cells. Blood.
2014 May 8;123(19):2988–2996.
43.
Zhou P, Blain AE, Newman AM, Zaka M, Chagaluka
G, Adlar FR, Offor UT, Broadbent C, Chaytor L, Whitehead A, Hall A,
O’Connor H, Van Noorden S, Lampert I, Bailey S, Molyneux E, Bacon CM,
Bomken S, Rand V. Sporadic and endemic Burkitt lymphoma
have frequent FOXO1 mutations but distinct hotspots in the
AKT recognition motif. Blood Adv. 2019 Jul
23;3(14):2118–2127. PMCID: PMC6650741
44.
Li
J, Chin CR, Ying HY, Meydan C, Teater MR, Xia M, Farinha P, Takata K,
Chu CS, Jiang Y, Eagles J, Passerini V, Tang Z, Rivas MA, Weigert O,
Pugh TJ, Chadburn A, Steidl C, Scott DW, Roeder RG, Mason CE, Zappasodi
R, Béguelin W, Melnick AM. Loss of CREBBP and
KMT2D cooperate to accelerate lymphomagenesis and shape the
lymphoma immune microenvironment. Nat Commun. 2024 Apr 3;15(1):2879.
PMCID: PMC10991284
45.
Rushton CK, Arthur SE, Alcaide M, Cheung M,
Jiang A, Coyle KM, Cleary KLS, Thomas N, Hilton LK, Michaud N, Daigle S,
Davidson J, Bushell K, Yu S, Rys RN, Jain M, Shepherd L, Marra MA,
Kuruvilla J, Crump M, Mann K, Assouline S, Connors JM, Steidl C, Cragg
MS, Scott DW, Johnson NA, Morin RD. Genetic and evolutionary patterns of
treatment resistance in relapsed B-cell
lymphoma. Blood Adv. 2020 Jul 14;4(13):2886–2898. PMCID: PMC7362366
46.
Ying CY, Dominguez-Sola D, Fabi M, Lorenz IC,
Bansal M, Califano A, Pasqualucci L, Basso K, Dalla-Favera R.
MEF2B Mutations Lead to De-Regulated
Expression of the BCL6 Oncogene in Diffuse
Large B-Cell Lymphoma and Follicular Lymphoma.
Blood. 120.
47.
Jingjing Z, Lei M, Jie Z, Sha C, Yapeng H,
Weimin Z, Chunluan Y. A novel
MEF2C mutation in lymphoid neoplasm diffuse large B-cell lymphoma promotes tumorigenesis by
increasing c-JUN expression. Naunyn Schmiedebergs Arch
Pharmacol. 2020 Aug;393(8):1549–1558.
48.
Giallongo A, Appella E, Ricciardi R, Rovera G,
Croce CM. Identification of the
c-myc oncogene product in normal and malignant B cells.
Science. 1983 Oct 28;222(4622):430–432.
49.
Christie L, Kernohan N, Levison D, Sales M,
Cunningham J, Gillespie K, Batstone P, Meiklejohn D, Goodlad J. C-MYC
translocation in t(14;18) positive follicular lymphoma at presentation:
An adverse prognostic indicator? Leuk Lymphoma. 2008
Mar;49(3):470–476.
50.
Johnston JM, Carroll WL. C-myc hypermutation in
Burkitt’s lymphoma. Leuk Lymphoma. 1992
Dec;8(6):431–439.
51.
Thomas RK, Wickenhauser C, Tawadros S, Diehl V,
Küppers R, Wolf J, Schmitz R. Mutational
analysis of the IkappaBalpha gene in activated
B cell-like diffuse large B-cell lymphoma. Br J Haematol. 2004
Jul;126(1):50–54.
52.
Morin RD, Assouline S, Alcaide M, Mohajeri A,
Johnston RL, Chong L, Grewal J, Yu S, Fornika D, Bushell K, Nielsen TH,
Petrogiannis-Haliotis T, Crump M, Tosikyan A, Grande BM, MacDonald D,
Rousseau C, Bayat M, Sesques P, Froment R, Albuquerque M, Monczak Y,
Oros KK, Greenwood C, Riazalhosseini Y, Arseneault M, Camlioglu E,
Constantin A, Pan-Hammarstrom Q, Peng R, Mann KK, Johnson NA. Genetic
Landscapes of Relapsed and Refractory
Diffuse Large B-Cell Lymphomas. Clin Cancer Res. 2016 May
1;22(9):2290–2300.
53.
Mansouri L, Noerenberg D, Young E, Mylonas E,
Abdulla M, Frick M, Asmar F, Ljungström V, Schneider M, Yoshida K,
Skaftason A, Pandzic T, Gonzalez B, Tasidou A, Waldhueter N,
Rivas-Delgado A, Angelopoulou M, Ziepert M, Arends CM, Couronné L, Lenze
D, Baldus CD, Bastard C, Okosun J, Fitzgibbon J, Dörken B, Drexler HG,
Roos-Weil D, Schmitt CA, Munch-Petersen HD, Zenz T, Hansmann ML,
Strefford JC, Enblad G, Bernard OA, Ralfkiaer E, Erlanson M,
Korkolopoulou P, Hultdin M, Papadaki T, Grønbæk K, Lopez-Guillermo A,
Ogawa S, Küppers R, Stamatopoulos K, Stavroyianni N, Kanellis G,
Rosenwald A, Campo E, Amini RM, Ott G, Vassilakopoulos TP, Hummel M,
Rosenquist R, Damm F. Frequent
NFKBIE deletions are associated with poor outcome in
primary mediastinal B-cell lymphoma.
Blood. 2016 Dec 8;128(23):2666–2670.
54.
Kridel R, Meissner B, Rogic S, Boyle M,
Telenius A, Woolcock B, Gunawardana J, Jenkins C, Cochrane C, Ben-Neriah
S, Tan K, Morin RD, Opat S, Sehn LH, Connors JM, Marra MA, Weng AP,
Steidl C, Gascoyne RD. Whole transcriptome
sequencing reveals recurrent NOTCH1 mutations in mantle
cell lymphoma. Blood. 2012 Mar 1;119(9):1963–1971.
55.
O’Hayre M, Inoue A, Kufareva I, Wang Z, Mikelis
CM, Drummond RA, Avino S, Finkel K, Kalim KW, DiPasquale G, Guo F, Aoki
J, Zheng Y, Lionakis MS, Molinolo AA, Gutkind JS. Inactivating mutations
in GNA13 and RHOA in Burkitt’s
lymphoma and diffuse large B-cell lymphoma:
A tumor suppressor function for the Gα13/RhoA
axis in B cells. Oncogene. 2016 Jul 21;35(29):3771–3780.
PMCID: PMC4885800
56.
Flori M, Schmid CA, Sumrall ET, Tzankov A, Law
CW, Robinson MD, Müller A. The hematopoietic
oncoprotein FOXP1 promotes tumor cell survival in diffuse
large B-cell lymphoma by repressing
S1PR2 signaling. Blood. 2016 Mar 17;127(11):1438–1448.
57.
Deng Q, Lakra P, Gou P, Yang H, Meydan C,
Teater M, Chin C, Zhang W, Dinh T, Hussein U, Li X, Rojas E, Liu W,
Reville PK, Kizhakeyil A, Barisic D, Parsons S, Wilson A, Henderson J,
Scull B, Gurumurthy C, Vega F, Chadburn A, Cuglievan B, El-Mallawany NK,
Allen C, Mason C, Melnick A, Green MR. SMARCA4 is a
haploinsufficient B cell lymphoma tumor suppressor that
fine-tunes centrocyte cell fate decisions. Cancer Cell. 2024 Apr
8;42(4):605–622.e11. PMCID: PMC11003852
58.
Wilda M, Bruch J, Harder L, Rawer D, Reiter A,
Borkhardt A, Woessmann W. Inactivation of the ARF-MDM-2-p53 pathway in sporadic
Burkitt’s lymphoma in children. Leukemia. 2004
Mar;18(3):584–588.
59.
Mareschal S, Dubois S, Viailly PJ, Bertrand P,
Bohers E, Maingonnat C, Jaïs JP, Tesson B, Ruminy P, Peyrouze P,
Copie-Bergman C, Fest T, Jo Molina T, Haioun C, Salles G, Tilly H,
Lecroq T, Leroy K, Jardin F. Whole exome sequencing of
relapsed/refractory patients expands the repertoire of somatic mutations
in diffuse large B-cell lymphoma. Genes
Chromosomes Cancer. 2016 Mar;55(3):251–267.
60.
Hakem A, El Ghamrasni S, Maire G, Lemmers B,
Karaskova J, Jurisicova A, Sanchez O, Squire J, Hakem R. Caspase-8 is
essential for maintaining chromosomal stability and suppressing B-cell lymphomagenesis. Blood. 2012 Apr
12;119(15):3495–3502.
61.
Shin SY, Lee ST, Kim HJ, Ki CS, Jung CW, Kim
JW, Kim SH. BRAF V600E and MAP2K1 mutations in
hairy cell leukemia and splenic marginal zone lymphoma cases. Ann Lab
Med. 2015 Mar;35(2):257–259. PMCID: PMC4330180


